EHA 2015 - European Hematology Association - June 11-14, 2015
Chronic Myeloid Leukemia - CML -20th Congress of EHA
SOME INTERESTING ABSTRACTS FOR CML
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE
INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS
KILLER IMMUNOGLOBULIN-LIKE RECEPTORS CAN PREDICT TKI TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS
ATTEMPT TO EARLY DISCONTINUE DASATINIB FIRST LINE IN CHRONIC PHASE CML PATIENTS IN EARLY MOLECULAR RESPONSE AND INCLUDED IN THE PROSPECTIVE OPTIM-DASATINIB TRIAL.
EFFICACY AND SAFETY OF FRONTLINE NILOTINIB IN 1089 EUROPEAN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENEST1ST FINAL ANALYSIS
LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE
HEALTH-RELATED QUALITY OF LIFE IN CML PATIENTS UNDER NILOTINIB FIRST-LINE TREATMENT: RESULTS OF A GERMAN SUB-STUDY WITHIN THE ENEST1ST TRIAL
PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL
LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS
DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL+ CML
IS GENERIC MESILATE OF IMATINIB LESS INFERIOR THAN GLIVEC?ANALISYS IN BRAZILIAN COHORT
OUTCOME OF FRONTLINE TREATMENT WITH GENERIC IMATINIB ACCORDING TO ELN 2009 BASED NATIONAL GUIDELINES. EXPERIENCE FROM UNIVERSITY CLINIC OF HEMATOLOGY, CLINICAL CENTER OF SERBIA, BELGRADE
ELEVATED BLOOD PRESSURE (BP) AND ADVERSE EVENTS OF HYPERTENSION (HTN) IN PHASE 1, 2, AND 3 TRIALS OF PONATINIB IN LEUKEMIA
T315I CLONE SELECTION IN A PHI+ ALL PATIENT UNDER MAINTENANCE PONATINIB
QUALITY OF LIVE IN PATIENTS WITH CML: QUESTIONNAIRE BASED STUDY
'REAL-LIFE' FRONTLINE DASATINIB TREATMENT IN UNSELECTED ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA
GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML
LONG-TERM BOSUTINIB FOR PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ADVANCED CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR TYROSINE KINASE INHIBITOR FAILURE
SIGNIFICANCE OF ANEMIA IN PATIENTS WITH CML AT DIAGNOSIS AND DURING THE TREATMENT WITH IMATINIB OUTSIDE THE CLINICAL TRIALS: CAMELIA REGISTRY EXPERIENCE
THE EFFICACY AND SAFETY OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER SWITCHING FROM GLIVEC: UPDATED DATA FROM CERRAHPAŞA CML COHORT
NEW TOOL FOR MONITORING MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
OPTIMIZATION OF THERAPEUTIC DOSES OF RADOTINIB FOR CHRONIC MYELOID LEUKEMIA BASED ON EXPOSURE-RESPONSE RELATIONSHIP ANALYSES
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE
INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS
KILLER IMMUNOGLOBULIN-LIKE RECEPTORS CAN PREDICT TKI TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS
ATTEMPT TO EARLY DISCONTINUE DASATINIB FIRST LINE IN CHRONIC PHASE CML PATIENTS IN EARLY MOLECULAR RESPONSE AND INCLUDED IN THE PROSPECTIVE OPTIM-DASATINIB TRIAL.
EFFICACY AND SAFETY OF FRONTLINE NILOTINIB IN 1089 EUROPEAN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENEST1ST FINAL ANALYSIS
LONG-TERM BOSUTINIB IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR IMATINIB FAILURE
HEALTH-RELATED QUALITY OF LIFE IN CML PATIENTS UNDER NILOTINIB FIRST-LINE TREATMENT: RESULTS OF A GERMAN SUB-STUDY WITHIN THE ENEST1ST TRIAL
PONATINIB EFFICACY AND SAFETY IN HEAVILY PRETREATED LEUKEMIA PATIENTS: 3-YEAR RESULTS OF THE PACE TRIAL
LONG-TERM FOLLOW-UP OF PONATINIB EFFICACY AND SAFETY IN PATIENTS (PTS) WITH THE T315I MUTATION IN THE PHASE 1 AND PHASE 2 (PACE) TRIALS
DEEP MOLECULAR RESPONSE TO NILOTINIB AS FIRST-LINE TREATMENT OF BCR-ABL+ CML
IS GENERIC MESILATE OF IMATINIB LESS INFERIOR THAN GLIVEC?ANALISYS IN BRAZILIAN COHORT
OUTCOME OF FRONTLINE TREATMENT WITH GENERIC IMATINIB ACCORDING TO ELN 2009 BASED NATIONAL GUIDELINES. EXPERIENCE FROM UNIVERSITY CLINIC OF HEMATOLOGY, CLINICAL CENTER OF SERBIA, BELGRADE
ELEVATED BLOOD PRESSURE (BP) AND ADVERSE EVENTS OF HYPERTENSION (HTN) IN PHASE 1, 2, AND 3 TRIALS OF PONATINIB IN LEUKEMIA
T315I CLONE SELECTION IN A PHI+ ALL PATIENT UNDER MAINTENANCE PONATINIB
QUALITY OF LIVE IN PATIENTS WITH CML: QUESTIONNAIRE BASED STUDY
'REAL-LIFE' FRONTLINE DASATINIB TREATMENT IN UNSELECTED ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA
GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML
LONG-TERM BOSUTINIB FOR PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ADVANCED CHRONIC MYELOID LEUKEMIA (CML) AFTER PRIOR TYROSINE KINASE INHIBITOR FAILURE
SIGNIFICANCE OF ANEMIA IN PATIENTS WITH CML AT DIAGNOSIS AND DURING THE TREATMENT WITH IMATINIB OUTSIDE THE CLINICAL TRIALS: CAMELIA REGISTRY EXPERIENCE
THE EFFICACY AND SAFETY OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER SWITCHING FROM GLIVEC: UPDATED DATA FROM CERRAHPAŞA CML COHORT
NEW TOOL FOR MONITORING MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
THE LYMPHOCYTE DYNAMICS PREDICTS THE BETTER RESPONSE FOR DASATINIB TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
OPTIMIZATION OF THERAPEUTIC DOSES OF RADOTINIB FOR CHRONIC MYELOID LEUKEMIA BASED ON EXPOSURE-RESPONSE RELATIONSHIP ANALYSES